Absci Corporation (ABSI) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Absci Corporation (NASDAQ: ABSI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $12.10 (+1.85% 1D, market cap $2.08B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABSI ranks #472 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ABSI carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OABI (OmniAb Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -22.6%, cap $760.4M) and NRC (NRC Health) posts a C grade (65/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
Per ABSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672688), Absci Corporation generated $0 in revenue (-100.0% YoY), -$115.2M in net income, and -$94.0M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 96% of 52W Range • RSI-14 at 57.7 (BULLISH MOMENTUM)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ABSI currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.51) and Max Pain ($12.71) forces dealer call-delta covering toward $13.44.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Absci Corporation (ABSI) advanced +1.85% to $12.10, trading at 96% of its 52-week range ($2.24 – $12.55). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Key TakeawaysAbsci fell 8% today as AI drug discovery peers Schrödinger and Recursion slid in a Nasdaq sell-off. These stocks trade together on sentiment, so the drop says little about Absci’s business.
Absci reported positive interim Phase 1 data for ABS-201 in pattern hair loss, including an estimated half-life of at least 65 days and timelines for proof-of-concept data in the second half of 2026 and full data in earl
Jefferies analyst Andrew Tsai initiates coverage on Absci (NASDAQ:ABSI) with a Buy rating and announces Price Target of $14.
Key TakeawaysAbsci rose 12% today, Schrödinger 11% and Recursion 9%, and no company news explains any of the three moves. Schrödinger’s rally has the most business behind it, and Absci’s rally is mostly about investors’
VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announc
Absci (ABSI) has drawn fresh attention after reporting positive interim Phase 1 data for ABS-201 in pattern hair loss, including an estimated half-life of at least 65 days for the antibody therapy. The latest ABS-201 upd
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ABSI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ABSI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Absci Corporation (ABSI) ranks #472 by composite RQD confidence (45/100, grade D) and #255 by equity capitalization ($2.08B). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with ABSI at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABSI
ACTIVE
Absci Corporation | D | 45/100 | — | — | -35.0% | +1.85% | $2.08B | Benchmark Subject |
| OABI OmniAb Inc. | D- | 38/100 | — | — | -22.6% | -0.95% | $760.4M | /oabi-vs-absi → |
| NRC NRC Health | C | 65/100 | 44.8x | — | 21.0% | +0.09% | $519.6M | /nrc-vs-absi → |
| ICLR ICON plc | B- | 71/100 | 71.9x | — | 3.1% | +0.62% | $16.50B | /iclr-vs-absi → |
| CRL Charles River Laboratories International Inc. | C | 63/100 | — | — | 0.4% | +0.57% | $17.95B | /crl-vs-absi → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Absci Corporation (ABSI) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $4.5M , and -100.0% cumulative change since FY2023) , GAAP net income of -$115.2M, operating cash flow of -$92.9M, and free cash flow of -$94.0M (-29.2% YoY). On the balance sheet, ABSI closed FY2025 with $216.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$115.2M | -$92.9M | -$94.0M | $216.3M | — |
| FY2024 (FY) | 2024-12-31 | $4.5M | -$103.1M | -$72.4M | -$72.8M | $213.6M | — |
| FY2023 (FY) | 2023-12-31 | $5.7M | -$110.6M | -$64.6M | -$64.6M | — | — |
As of 2026-11-01, Absci Corporation (NASDAQ: ABSI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $12.10 (+1.85% 1D, market cap $2.08B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABSI ranks #472 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ABSI carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OABI (OmniAb Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -22.6%, cap $760.4M) and NRC (NRC Health) posts a C grade (65/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
Per ABSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672688), Absci Corporation generated $0 in revenue (-100.0% YoY), -$115.2M in net income, and -$94.0M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ABSI last traded at $12.10 (+1.85% on volume of 4,337,446 shares), positioning the stock +27.23% above its 50-day simple moving average ($9.51) and +86.44% above its 200-day simple moving average ($6.49). Across its 52-week range of $2.24 to $12.55, ABSI sits at the 95.6% percentile with a 14-day RSI of 57.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($10.59 to $13.61).
Why ABSI Stock advanced +1.85% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.